Literature DB >> 8823527

Physiological and pathological roles of parathyroid hormone-related peptide.

T A Guise1, G R Mundy.   

Abstract

Parathyroid hormone-related peptide was originally identified as a tumor-produced factor that mediated malignancy-associated hypercalcemia by binding to the common parathyroid hormone/parathyroid hormone-related peptide receptor to stimulate osteoclastic bone resorption and renal tubular resorption of calcium. Its role as a humoral factor in hypercalcemia of malignancy is well established, and recent work has demonstrated its importance as a tumor-produced factor in the pathogenesis of bone metastasis. Besides these cancer-related functions, work in the past decade has clearly established that parathyroid hormone-related peptide has many important functions in normal physiology related to growth and development, reproductive function and smooth muscle relaxation. Many other physiological functions are also being attributed to this versatile peptide. An understanding of these functions in malignancy and normal physiology should lead to innovative therapy for malignancy as well as other disorders not previously related to calcium homeostasis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823527     DOI: 10.1097/00041552-199607000-00004

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  6 in total

Review 1.  PTHrP gene expression in cancer: do all paths lead to Ets?

Authors:  Virgile Richard; Thomas J Rosol; John Foley
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2005       Impact factor: 1.807

2.  Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study.

Authors:  Emanuela Palmerini; Laura Pazzaglia; Luca Cevolani; Loredana Pratelli; Michela Pierini; Irene Quattrini; Elisa Carretta; Maria Cristina Manara; Michela Pasello; Giorgio Frega; Anna Paioli; Alessandra Longhi; Marilena Cesari; Rossella Hakim; Toni Ibrahim; Laura Campanacci; Eric Lodewijk Staals; Davide Maria Donati; Maria Serena Benassi; Katia Scotlandi; Stefano Ferrari
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

3.  Halofuginone inhibits the establishment and progression of melanoma bone metastases.

Authors:  Patricia Juárez; Khalid S Mohammad; Juan Juan Yin; Pierrick G J Fournier; Ryan C McKenna; Holly W Davis; Xiang H Peng; Maria Niewolna; Delphine Javelaud; John M Chirgwin; Alain Mauviel; Theresa A Guise
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

4.  Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone.

Authors:  Jennifer L Gilmore; Ryan M Gonterman; Keshav Menon; Gwendolen Lorch; David J Riese; Alex Robling; John Foley
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

5.  Structural basis for antibody discrimination between two hormones that recognize the parathyroid hormone receptor.

Authors:  William J McKinstry; Galina Polekhina; Hannelore Diefenbach-Jagger; Patricia W M Ho; Koh Sato; Etsuro Onuma; Matthew T Gillespie; T John Martin; Michael W Parker
Journal:  J Biol Chem       Date:  2009-04-04       Impact factor: 5.157

Review 6.  Calcium-sensing receptor in cancer: good cop or bad cop?

Authors:  Bandana Chakravarti; Shailendra Kumar Dhar Dwivedi; Ambrish Mithal; Naibedya Chattopadhyay
Journal:  Endocrine       Date:  2008-11-15       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.